Oxurion releases phase 1/2 data of clinical study evaluating TR-317 for DME

THR-317 for the treatment of diabetic macular edema met its primary safety endpoint in a phase 1/2 study and also demonstrated efficacy, according to a press release from Oxurion.
Anat Loewenstein, MD , MHA, professor of ophthalmology, chair of the ophthalmology division at Tel Aviv Medical Center, presented the clinical-stage data at FLORetina 2019. Two dose levels, 4 mg and 8 mg, of the anti-placental growth factor candidate THR-317 were evaluated for safety and efficacy in 49 patients with DME, including anti-VEGF-naive patients and suboptimal anti-VEGF responders.
Both groups met the

Full Story →